PARRY, ROMANI, DECONCINI & SYMMS for SANOFI US SERVICES INC (FORMERLY KNOWN AS SANOFI-AVENTIS U S INC )
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Economics/Economic Development ECN
H.R. 2052 / S. 1023, Global Investment in American Jobs Act of 2013
Foreign entity interest: Sanofi SA, the foreign parent corporation of Sanofi US Services Inc.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD H BAXTER | — |
| ROMANO ROMANI | — |
| STEVE SYMMS | — |
Copyright/Patent/Trademark CPT
Monitored consideration of patent legislation; S. 1013, the Patent Abuse Reduction Act of 2013; S. 1612, Patent Litigation Integrity Act of 2013; and H.R. 3309, the Innovation Act.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD H BAXTER | — |
| ROMANO ROMANI | — |
| STEVE SYMMS | — |
Health Issues HCR
General issues related to prescription drug safety and the importation of prescription drugs. General issues regarding implementation of Public Law 111-148, Patient Protection and Affordable Care Act (ACT). Support H.R. 2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD H BAXTER | — |
| ROMANO ROMANI | — |
| STEVE SYMMS | — |
Medicare/Medicaid MMM
General issues related to changes to Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement issues for those who are covered by the Medicaid program and the Medicare program; including the Part D prescription drug benefit.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD H BAXTER | — |
| ROMANO ROMANI | — |
| STEVE SYMMS | — |
Medical/Disease Research/Clinical Labs MED
Support H.R. 2985, the Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.
Foreign entity interest: Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| EDWARD H BAXTER | — |
| ROMANO ROMANI | — |
| STEVE SYMMS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.